跳至主要内容
临床试验/NCT01317563
NCT01317563已完成2 期

Phase 2 Study of Antioxidant Therapy in Lean and Obese Asthmatics

Nemours Children's Clinic1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2008年7月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
43
试验地点
1
主要终点
Change in Asthma Control Questionnaire (Juniper)- (ACQ)

研究概览

简要总结

This project will assess the effectiveness of antioxidant supplementation with common vitamins A, C, E and selenium in controlling asthma symptoms among lean and obese asthmatics. This project may improve our ability to treat asthma and our understanding of the link between nutritional antioxidants and asthma.

详细描述

Asthma & Obesity are both growing public health crises that also may be critically interrelated for many patients. Obesity increases the risk for asthma in both adults and children, and obesity increases the severity of existing asthma. Obesity leads to increased systemic oxidative stress, however little is know about obesity-related oxidative stress within the airway. Since oxidative stress contributes to the pathogenesis of asthma, obesity may influence asthma risk and severity through this mechanism. Asthmatics have low serum antioxidant activity. There is conflicting evidence about whether or not antioxidant supplementation reduces asthma severity. This may be related to asthma's heterogeneous nature. Antioxidant supplementation may be effective in select subgroups that have the greater oxidative stress, such as asthmatics with occupational exposures or obesity. In fact, the evidence supporting antioxidant supplementation in asthma involved subjects with oxidant-related triggers. We hypothesize that obesity-related oxidant stress puts asthmatics at risk for increased airway oxidative stress and greater asthma severity. We hypothesize that supplementation with common antioxidants will significantly reduce airway inflammation and oxidative stress, and lead to improved pulmonary function and daily asthma control. This pilot study is designed as a randomized, double-blinded, placebo-controlled, parallel intervention trial involving lean and obese adolescents and young adults with asthma. After the 2-week run-in period, all subjects will undergo baseline testing (see figure 1). At randomization they will receive either placebo or a multivitamin antioxidant for 42 days. At the end of the 42 day intervention all subjects will undergo final testing. Primary Hypothesis: In young asthmatics, antioxidant supplementation increases plasma and airway antioxidant levels leading to improved lung function and asthma control. Secondary Hypotheses: 1) Obesity-related systemic oxidant stress is associated with increased oxidative stress within the airway. 2) Antioxidant supplementation will lead to greater improvements in asthma control among obese compared to lean (not underweight) asthmatics. 3) Antioxidant supplementation will lead to greater improvements in airway markers of inflammation and oxidative stress among obese compared to lean asthmatics. We will assess asthma control and lung function before and after therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
12 Years 至 25 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •age 12-25,
  • •physician-diagnosed persistent asthma on daily controller therapy,
  • •FEV1% >= 60% predicted,
  • •Lung responsiveness (>= 12% BD reversibility or PC20 MCT <= 16mg/ml)

排除标准

  • •taking daily MVI,
  • •chronic oral steroid therapy,
  • •BMI<20th percentile,
  • •smoking history,
  • •pregnancy,
  • •milk allergy,
  • •celiac disease

研究组 & 干预措施

Antioxidant arm

Active Comparator

Two capsules twice daily (total daily dose = Vitamin A 10000 IU, Vitamin C 1200mg, Vitamin E 400 IU, Selenium 300mcg)

干预措施: Vitamins A, E, C & Selenium (Dietary Supplement)

Placebo arm

Placebo Comparator

two capsules twice daily (total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose)

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Change in Asthma Control Questionnaire (Juniper)- (ACQ)

时间窗: 6 weeks

ACQ is a 7 component test that includes 6 responses elliciting control of asthma symptoms plus one component based on FEV1 (spirometry). The score ranges from 0-6, with a higher score suggesting greater asthma symptoms.

次要结局

  • change in FEV1(6 weeks)
  • Change in Asthma Symptom Utility Index(6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jason Lang

PI

Nemours Children's Clinic

研究点 (1)

Loading locations...

相似试验

Antioxidant Therapy in Lean and Obese Asthmatics | 临床试验